Tech Company Financing Transactions
Invizius Funding Round
Mercia Ventures, Calculus Capital and Old College Capital participated in a $1.3 million capital raise for Invizius. The funding round was announced by the company on 9/23/2024.
Transaction Overview
Company Name
Announced On
9/23/2024
Transaction Type
Venture Equity
Amount
$1,300,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to prepare for the next stage of clinical trials of its H-Guard product in continuous renal replacement therapy (CRRT), a type of dialysis used in cases of acute kidney injury in an intensive care unit (ICU), and will assess its impact in modifying the immune response and reducing renal tubule damage.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
2nd Floor, Murchison House, 10 Max Born Crescent
Edinburgh, EH9 3BF
UK
Edinburgh, EH9 3BF
UK
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Invizius is a clinical stage biotech developing second generation complement therapies to treat inflammatory, fibrotic and autoimmune disorders. Our proprietary technology harnesses and supercharges natural complement regulators to maximise potential patient safety and clinical efficacy.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Eric Beard
Chief Executive Officer
Magnus Nicolson
Co-Founder
Eliza Makou
Browse more venture capital transactions:
Prev: 9/23/2024: FluoRok venture capital transaction
Next: 9/23/2024: Agents World venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on tech company VC transactions. All VC database entries reported here are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs